SCHEMBL2196704

SCHEMBL2196704

CS(=O)(=O)CCNCCn1cc2c(n1)CCc1c-2sc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 20/20 0.55
ERBB2 P04626 14/20 0.55
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
MAPK1 P28482 2/20 0.50
CYP3A4 P08684 2/20 0.49
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49
ALOX15 P16050 1/20 0.49
HSD17B10 Q99714 1/20 0.49
PIK3C2B O00750 1/20 0.49
MAP2K7 O14733 1/20 0.49
RIPK2 O43353 1/20 0.49
PIK3C2G O75747 1/20 0.49
STK10 O94804 1/20 0.49
ABCB11 O95342 1/20 0.49
ABL1 P00519 1/20 0.49
INSR P06213 1/20 0.49
RET P07949 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2197663 0.91 EGFR (0.57) EGFRERBB2
SCHEMBL9947568 0.91 EGFR (0.52) EGFRERBB2MEN1KMT2AMAPK1
SCHEMBL2194129 0.91 EGFR (0.59) EGFRERBB2
SCHEMBL2196131 0.90 EGFR (0.57) EGFRERBB2
SCHEMBL2196716 0.90 EGFR (0.61) EGFRERBB2
SCHEMBL2196428 0.90 EGFR (0.54) EGFRERBB2MEN1KMT2AMAPK1
SCHEMBL2192524 0.90 EGFR (0.57) EGFRERBB2
SCHEMBL2195244 0.90 EGFR (0.59) EGFRERBB2
SCHEMBL10227916 0.89 EGFR (0.62) EGFRERBB2
SCHEMBL2195628 0.88 EGFR (0.63) EGFRERBB2ERBB3ERBB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207172-B2 Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-26 US disclosed
US-8207172-B2 Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-26 US disclosed
US-8207172-B2 Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-26 US disclosed
US-20110172224-A1 NOVEL HETEROCYCLES BAYER PHARMACEUTICALS CORPORATION (US) 2011-07-14 US disclosed
US-20110172224-A1 NOVEL HETEROCYCLES BAYER PHARMACEUTICALS CORPORATION (US) 2011-07-14 US disclosed
US-20110172224-A1 NOVEL HETEROCYCLES BAYER PHARMACEUTICALS CORPORATION (US) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172224-A1 NOVEL HETEROCYCLES CCNI, PCNA, CCNA1 EGFR 2146/4885ERBB2 1762/4885MEN1 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.